Boston Scientific Corporation (BSX)
Market Cap | 149.59B |
Revenue (ttm) | 17.55B |
Net Income (ttm) | 2.03B |
Shares Out | 1.48B |
EPS (ttm) | 1.37 |
PE Ratio | 73.80 |
Forward PE | 34.31 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 8,983,607 |
Open | 99.28 |
Previous Close | 98.92 |
Day's Range | 99.28 - 101.68 |
52-Week Range | 70.97 - 107.17 |
Beta | 0.73 |
Analysts | Strong Buy |
Price Target | 110.26 (+9.02%) |
Earnings Date | Apr 23, 2025 |
About BSX
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices ... [Read more]
Financial Performance
In 2024, Boston Scientific's revenue was $16.75 billion, an increase of 17.61% compared to the previous year's $14.24 billion. Earnings were $1.85 billion, an increase of 18.03%.
Financial StatementsAnalyst Forecast
According to 23 analysts, the average rating for BSX stock is "Strong Buy." The 12-month stock price forecast is $110.26, which is an increase of 9.02% from the latest price.
News

Second phase of ADVANTAGE AF study of FARAPULSE™ Pulsed Field Ablation System meets primary safety and efficacy endpoints
Trial achieves positive results in the treatment of persistent atrial fibrillation MARLBOROUGH, Mass. and SAN DIEGO , April 24, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today ann...

Boston Scientific Analysts Boost Their Forecasts Following Upbeat Results
Boston Scientific Corporation BSX posted better-than-expected earnings for the first quarter on Wednesday.

Boston Scientific Corporation (BSX) Q1 2025 Earnings Call Transcript
Boston Scientific Corporation (NYSE:BSX) Q1 2025 Results Conference Call April 23, 2025 8:00 AM ET Company Participants Jon Monson - Senior Vice President, Investor Relations Mike Mahoney - Chairman ...

Boston Scientific Raises Annual Outlook After Strong Heart Devices Sales In Q1, Announces CFO Transition
Boston Scientific Corporation BSX on Wednesday reported first-quarter 2025 revenues of $4.66 billion, beating the consensus estimate of $4.57 billion.

Boston Scientific Stock Surges on Strong Results, Outlook; CFO To Retire
Shares of Boston Scientific (BSX) rose sharply Wednesday after the firm posted first-quarter results that topped analysts' estimates.

Boston Scientific raises 2025 profit forecast on strong heart device sales
Boston Scientific raised its annual profit forecast after strong sales of its heart devices helped beat Wall Street expectations for first-quarter profit.

Boston Scientific Chief Financial Officer (CFO) Dan Brennan to retire; Jon Monson, senior vice president, Investor Relations to succeed Brennan
MARLBOROUGH, Mass. , April 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that Dan Brennan, executive vice president and chief financial officer, has elected to ret...

Boston Scientific announces results for first quarter 2025
MARLBOROUGH, Mass. , April 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.663 billion during the first quarter of 2025, growing 20.9 percent on a reported...

Goldman Sachs Thinks These Stocks Are ‘Insulated' From a Trade War
Amdocs, Kroger, Bank of New York Mellon and Valvoline lead a list of stocks that Goldman Sachs calls “insensitive” to market volatility.

Boston Scientific announces conference call discussing first quarter 2025 results
MARLBOROUGH, Mass. , April 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter...

Boston Scientific Corporation (BSX) TD Cowen 45th Annual Healthcare Conference (Transcript)
Boston Scientific Corporation (NYSE:BSX) TD Cowen 45th Annual Healthcare Conference March 4, 2025 9:10 AM ET Company Participants Dan Brennan - Chief Financial Officer Ken Stein - Chief Medical Offic...

Boston Scientific announces agreement to acquire SoniVie Ltd.
Acquisition to expand Interventional Cardiology Therapies offerings with ultrasound-based renal denervation therapy for treatment of hypertension MARLBOROUGH, Mass. , March 3, 2025 /PRNewswire/ -- Bos...

Boston Scientific announces completion of €1.5 billion offering of senior notes
MARLBOROUGH, Mass. , Feb. 26, 2025 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE: BSX) today announced that American Medical Systems Europe B.V.

Balloon Catheters Patent Landscape Report 2025, with Profiles of Cook Medical Technologies, Boston Scientific Scimed, Scimed Life Systems, Terumo Corp and Advanced Cardiovascular System
Dublin, Feb. 24, 2025 (GLOBE NEWSWIRE) -- The "Balloon Catheters Patent Landscape Report" has been added to ResearchAndMarkets.com's offering.

Boston Scientific announces pricing of €1.5 billion of senior notes
MARLBOROUGH, Mass. , Feb. 21, 2025 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE: BSX) today announced that American Medical Systems Europe B.V.

Boston Scientific to participate in TD Cowen's 45th Annual Health Care Conference
MARLBOROUGH, Mass. , Feb. 19, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in TD Cowen's 45th Annual Health Care Conference on Tuesday, March 4, 2025.

What's Behind The 130% Rise In BSX Stock?
Boston Scientific stock (NYSE: BSX) has gained 3% in the five days since its Q4 earnings report last week. Although the company exceeded expectations with both its results and guidance, the modest sto...

Boston Scientific Corporation (BSX) Q4 2024 Earnings Call Transcript
Boston Scientific Corporation (NYSE:BSX) Q4 2024 Earnings Conference Call February 5, 2025 8:00 AM ET Company Participants Jonathan Monson - SVP, IR Michael Mahoney - Chairman and CEO Daniel Brennan ...

Boston Scientific sees higher-than-expected 2025 profit on strong demand
Medical device maker Boston Scientific forecast annual profit above Wall Street estimates on Wednesday, banking on steady demand for its heart devices.

Boston Scientific announces results for fourth quarter and full year 2024
MARLBOROUGH, Mass. , Feb. 5, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.561 billion during the fourth quarter of 2024, growing 22.4 percent on a reported ...

Top 4 Health Care Stocks You May Want To Dump In Q1
As of Jan. 21, 2025, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Late-breaking data presented at AF Symposium 2025 highlight key Boston Scientific therapies for management of patients with atrial fibrillation
First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed Field Abl...

Boston Scientific Jumps Ahead of Earnings
Boston Scientific Corporation (BSX) shares rise on acquisitions – earnings due in early February.
Stocks on the move: Delta, Constellation Energy, Wynn, Sweetgreen and Boston Scientific
The Investment Committee discuss some stocks on the move today.